Feedback
Settings

Settings

Goto Application

1. WO2022044014 - COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA

Submit observation
PermaLink
Publication Number WO/2022/044014
Publication Date 03.03.2022
International Application No. PCT/IL2021/051048
International Filing Date 26.08.2021
IPC
A61K 31/216 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
216of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/7036 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
7036having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 33/243 2019.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
243Platinum; Compounds thereof
A61K 38/13 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
13Cyclosporins
A61P 13/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61K 31/7048 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
CPC
A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 31/216
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
216of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/7036
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
7036having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/7048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin ; digitoxin or digoxin
A61K 33/243
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
243Platinum; Compounds thereof
A61K 38/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides ; , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
13Cyclosporins
Applicants
  • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. [IL]/[IL]
Inventors
  • NAHMIAS, Yaakov
  • COHEN, Aaron
  • EHRLICH, Avner
Agents
  • EHRLICH, Gal
Priority Data
63/070,39126.08.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA
(FR) POLYTHÉRAPIE POUR RÉDUIRE LA NÉPHROTOXICITÉ, LA DYSLIPIDÉMIE ET L'HYPERGLYCÉMIE INDUITES PAR UN MÉDICAMENT
front page image
Abstract
(EN) Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C/EBP, PPARG, ER stress, GLUT2 and SGLT1/2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C/EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.
(FR) L'invention concerne des procédés, des compositions et des kits pour réduire la toxicité des tissus rénaux chez un sujet, provoquée par un agent endommageant les reins. Les procédés comprennent administrer au sujet : (i) un agent endommageant les reins ; (ii) un activateur de PPARA ; et (iii) un inhibiteur d'une voie cellulaire choisie dans le groupe consistant en C/EBP, PPARG, stress du RE, GLUT2 et SGLT1/2 ; ou (i) un agent endommageant les reins ; (ii) un inhibiteur de SGLT2 ; et (iii) un activateur de PPARA, un inhibiteur de C/EBP, un inhibiteur de PPARG, ou un inhibiteur du stress de RE.
Latest bibliographic data on file with the International Bureau
# -